Vinflunine treatment in patients with metastatic urothelial cancer: A Nordic retrospective multicenter analysis

Vinflunine treatment in patients with metastatic urothelial cancer: A Nordic retrospective multicenter analysis

In 2009, vinflunine was introduced as a second-line treatment to be used after the failure of platinum therapy in patients with metastatic urothelial carcinoma (mUC). The present study investigated the administered vinflunine to patients with mUC in standard clinical practice with the aim of evaluat...

Full description

Bibliographic Details
Main Authors: Holmsten, Karin, Dohn, Line, Jensen, Niels Viggo, Shah, Carl-Henrik, Jäderling, Fredrik, Pappot, Helle, Ullén, Anders
Format: Online
Language:English
Published: D.A. Spandidos 2016
Online Access:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4950730/
id pubmed-4950730
recordtype oai_dc
spelling pubmed-49507302016-07-21 Vinflunine treatment in patients with metastatic urothelial cancer: A Nordic retrospective multicenter analysis Holmsten, Karin Dohn, Line Jensen, Niels Viggo Shah, Carl-Henrik Jäderling, Fredrik Pappot, Helle Ullén, Anders Articles In 2009, vinflunine was introduced as a second-line treatment to be used after the failure of platinum therapy in patients with metastatic urothelial carcinoma (mUC). The present study investigated the administered vinflunine to patients with mUC in standard clinical practice with the aim of evaluating treatment patterns, response, survival parameters and side-effects. Data were collected retrospectively from the first 100 mUC patients treated with vinflunine at three Nordic cancer centers associated with the Nordic Urothelial Cancer Oncology Group. The overall response rate was 23% and complete response was observed in one patient. The median progression-free survival (mPFS) and median overall survival (mOS) were 2.8 (range, 0.5–34.3) and 6.3 (range, 0.3–39.7) months, respectively. An Eastern Cooperative Oncology Group performance status (ECOG PS) of 2 was present in 20% of the patients, and those patients exhibited significantly shorter mOS (4.1 vs. 7.0 months, P=0.001) and a significantly higher degree of grade 3/4 toxicity (P=0.026) compared with ECOG PS 0–1 patients. Furthermore, patients without visceral metastases had significantly longer mOS than patients with visceral metastases (10.6 vs. 6.0 months, P=0.008). The median number of cycles of vinflunine was 3 (range, 1–28). The current data confirms that vinflunine is an active agent for second-line treatment in an unselected clinical cohort of patients with mUC. ECOG PS and presence of visceral metastases were significant prognostic parameters. In particular, patients with ECOG PS 2 receiving vinflunine had a shorter mOS and a higher frequency of severe toxicity, and, thus, should be treated with caution. Furthermore, the present study observed large inter-individual differences in radiological response and OS, indicating the need for further development of improved patient selection tools to optimize vinflunine treatment in platinum-refractory mUC patients. D.A. Spandidos 2016-08 2016-06-23 /pmc/articles/PMC4950730/ /pubmed/27446429 http://dx.doi.org/10.3892/ol.2016.4775 Text en Copyright: © Holmsten et al. This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License (https://creativecommons.org/licenses/by-nc-nd/4.0/) , which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.
repository_type Open Access Journal
institution_category Foreign Institution
institution US National Center for Biotechnology Information
building NCBI PubMed
collection Online Access
language English
format Online
author Holmsten, Karin
Dohn, Line
Jensen, Niels Viggo
Shah, Carl-Henrik
Jäderling, Fredrik
Pappot, Helle
Ullén, Anders
spellingShingle Holmsten, Karin
Dohn, Line
Jensen, Niels Viggo
Shah, Carl-Henrik
Jäderling, Fredrik
Pappot, Helle
Ullén, Anders
Vinflunine treatment in patients with metastatic urothelial cancer: A Nordic retrospective multicenter analysis
author_facet Holmsten, Karin
Dohn, Line
Jensen, Niels Viggo
Shah, Carl-Henrik
Jäderling, Fredrik
Pappot, Helle
Ullén, Anders
author_sort Holmsten, Karin
title Vinflunine treatment in patients with metastatic urothelial cancer: A Nordic retrospective multicenter analysis
title_short Vinflunine treatment in patients with metastatic urothelial cancer: A Nordic retrospective multicenter analysis
title_full Vinflunine treatment in patients with metastatic urothelial cancer: A Nordic retrospective multicenter analysis
title_fullStr Vinflunine treatment in patients with metastatic urothelial cancer: A Nordic retrospective multicenter analysis
title_full_unstemmed Vinflunine treatment in patients with metastatic urothelial cancer: A Nordic retrospective multicenter analysis
title_sort vinflunine treatment in patients with metastatic urothelial cancer: a nordic retrospective multicenter analysis
description In 2009, vinflunine was introduced as a second-line treatment to be used after the failure of platinum therapy in patients with metastatic urothelial carcinoma (mUC). The present study investigated the administered vinflunine to patients with mUC in standard clinical practice with the aim of evaluating treatment patterns, response, survival parameters and side-effects. Data were collected retrospectively from the first 100 mUC patients treated with vinflunine at three Nordic cancer centers associated with the Nordic Urothelial Cancer Oncology Group. The overall response rate was 23% and complete response was observed in one patient. The median progression-free survival (mPFS) and median overall survival (mOS) were 2.8 (range, 0.5–34.3) and 6.3 (range, 0.3–39.7) months, respectively. An Eastern Cooperative Oncology Group performance status (ECOG PS) of 2 was present in 20% of the patients, and those patients exhibited significantly shorter mOS (4.1 vs. 7.0 months, P=0.001) and a significantly higher degree of grade 3/4 toxicity (P=0.026) compared with ECOG PS 0–1 patients. Furthermore, patients without visceral metastases had significantly longer mOS than patients with visceral metastases (10.6 vs. 6.0 months, P=0.008). The median number of cycles of vinflunine was 3 (range, 1–28). The current data confirms that vinflunine is an active agent for second-line treatment in an unselected clinical cohort of patients with mUC. ECOG PS and presence of visceral metastases were significant prognostic parameters. In particular, patients with ECOG PS 2 receiving vinflunine had a shorter mOS and a higher frequency of severe toxicity, and, thus, should be treated with caution. Furthermore, the present study observed large inter-individual differences in radiological response and OS, indicating the need for further development of improved patient selection tools to optimize vinflunine treatment in platinum-refractory mUC patients.
publisher D.A. Spandidos
publishDate 2016
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4950730/
_version_ 1613611738862714880

Similar Items